신신제약

002800KOSDAQ

73.5 / 100

Reference Date: 2026-09-08

Financial Score32.0 / 40

News Sentiment17.5 / 25

Momentum14.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health and PER is significantly undervalued vs. peers is also solid. Rose 7.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Shinshin Pharmaceutical specializes in manufacturing and selling OTC medications, particularly topical products for muscle and joint pain. The company primarily sells to pharmacies and wholesale distributors, maintaining direct sales with over 12,000 pharmacies nationwide and actively expanding exports, especially to Southeast Asia.

Number of Employees

369people

Average Salary

59.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

7.55Industry Average 15.006.5Point

Lower than industry avg (good)

PBR

0.94Industry Average 1.204.0Point

In line with industry avg

ROE

13.25Industry Average 8.005.5Point

1.7x industry avg (good)

Debt Ratio

3.51Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20258.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲5.3% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲35.7% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 9.5% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 1Negative 0Average Sentiment Score 70

Positive
아렉스, 한 장으로 냉·온찜질…근육·관절통 필수품
신신파스 아렉스의 다양한 제형 확장으로 소비자 통증 관리 수요에 효과적으로 대응하며 기업의 지속적인 혁신을 인정받았다.
Neutral
매운맛 '캡사이신'이 위 보호하고 소화제로 쓰인다?
Capacinine's dual role in pain relief and digestive aid discussed without direct impact on 신신제약's stock performance.

Detailed Momentum

52-week position3.0Point

52w lower range (23%)

Current 4,630Won52-week high 6,63052-week low 4,015

1-month return5.0Point

1m +7.18% (rising)

Volume trend6.0Point

Volume surge

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14